

14th April 2023



SPIVA® update: Active managers struggled in 2022

- Active managers mainly underperformed benchmarks in 2022
- Failed to take advantage of dispersion, but UK small caps a bright spot
- Persistency remains a challenge

Financial markets in 2022 were volatile. Central banks were (and still are) hawkish over rampant inflation which, in the UK, reached a 41-year high in October at 11.1%¹. This combined with supply chain disruptions, geopolitical tensions and an energy crisis, led to equities featuring high dispersion and having their worst year since 2008². The high level of dispersion in both sector and company performance created the kind of backdrop where active managers should have thrived.

Active fund managers have long claimed that their strategies are better suited for navigating volatile markets, like those we saw in 2022, owing to the flexibility they have to adjust portfolios and take advantage of mispricing. Whilst index trackers fall with their indices, active managers can be selective. As such, they should have had greater potential to beat the benchmark. However, the latest SPIVA®³ (§&P Indices Versus Active) scorecard⁴ does not paint a favourable picture for active managers.

For 2022, only 26.78% of active global equity funds and 7.8% of active UK equity funds outperformed the benchmark on an absolute return basis.

The percentage of GBP-priced equity funds by region outperforming their related benchmark can be seen below on a 1, 3, 5 and 10 year basis.

-

¹ https://www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/october2022


² https://www.dimensional.com/us-en/insights/market-review-2022-after-a-down-year-looking-to-the-past-as-a-quide

³ Note: SPIVA® is a registered trademarks of S&P Global, Inc. ("S&P Global") or its affiliates.

⁴ SPIVA Scorecard as at end 2022: https://www.spglobal.com/spdji/en/documents/spiva/spiva-europe-year-end-2021.pdf



Fig.1. Percentage of equity funds by region outperforming related benchmark




As illustrated by the chart above, we can see that in the course of the past year, active managers fared best in European markets where over 40% beat the benchmark in 2022.

Looking within the UK equity market, we can see that there continues to be greatest potential for alpha in the small-cap segmentwhere approximately 80% of active managers beat their benchmark over 3 years. This suggests that for small caps, looking to a specialist active manager could make sense.



Fig.2. Percentage of UK equity funds by segment outperforming related benchmark



If we look at the SPIVA® results for each of the last 8 years, we can see significant variation over the 1 and 3 year time frames, but results tend to be fairly stable over 10 years. This is the evidence some cite when arguing that it is hard for active managers to persistently beat a related benchmark over time.

Fig.3 Percentage of Global equity funds outperforming related benchmark over rolling 10 year periods (as at year-end)







Fig.4 Percentage of Global equity funds outperforming related benchmark: 2022 vs 2021 results


Comparing 2022 SPIVA® results to 2021 results, we can see that the challenges of 2022 have marked down the global equity sector from 2021 to 2022.



Finally, comparing 2022 SPIVA® results to 2021 results, we can see that the challenges of 2022 contributed to a significant drop in UK active managers' near-term performance between 2021 and 2022. Only 7.8%, 22.7% and 21.3% of UK equity large cap active funds outperformed their index over 1, 3 and 5 years respectively.



Fig.5 Percentage of UK equity funds outperforming related benchmark: 2022 vs 2021 results



Source: Elston research, S&P Dow Jones Indices SPIVA Europe scorecard data as at December 2015-22 (GBP denominated funds). Includes interpolated data between 1&3 and 5&10 years for illustration only

With increasing focus on value for money, the search for active funds that can persistently deliver alpha remains a challenge. Consideration of market efficiency and market regime have a role to play.

Oliver Burrows

Associate, Elston Consulting

For more on this topic

Insights: 22nd October 2021: <u>Understanding SPIVA</u>

CPD Webinar: Is Active Management a Zero-Sum Game?

For all our Research & Insights, visit:

https://www.elstonsolutions.co.uk/insights





Find out more

For more insights and information on research, portfolios and indices, visit:

www.elstonsolutions.co.uk or NH ETF<Go>

www.elstonsolutions.co.uk

ABOUT ELSTON

We research, design and build investment solutions with and for asset owners, managers and advisers.

Our Research & CPD focuses on multi-asset strategies, index funds and ETFs.

NOTICES

With reference to the European Union Directive 2014/65/EU on markets in financial instruments ("MiFID II"): this Report does not provide a recommendation for an action, provides information freely available for public consumption and does not therefore constitute "Research" as defined by MiFID II. This is because this report contains purely factual information on one or several financial instruments or issuers and does not explicitly or implicitly recommend or suggest an investment strategy. It does not therefore constitute an investment recommendation as defined within the meaning of Article 3(1)(35) of EU Markets Abuse Regulation ("MAR"), in conjunction with Article 3(1)(34) of MAR. For further information, please refer to ESMA guidance ESMA70-145-111 Version 12.

With reference to the European Union's Market Abuse Regulation (Regulation (EU) 596/2014): we warrant that the information in this report is presented objectively, and the following commercial interests are hereby disclosed: Elston Consulting Limited creates research portfolios and administers indices that may or may not be referenced in this report. If referenced, this is clearly designated and is to raise awareness and provide purely factual information as regards these portfolios and/or indices.

An "Index" is a Regulated Benchmark. An "Index Portfolio" is not a regulated benchmark but a research portfolio of index-tracking investments with a periodic rebalancing scheme.

All company, product and service names and trademarks used in this article are for identification purposes only and are the property of their respective owners, and their usage does not imply endorsement.

This document is not an advertisement or financial promotion. It is provided for informational purposes only and is not intended to be an offer or solicitation, or the basis for any contract to purchase or sell any security or other instrument, or for Elston Consulting Limited to enter into or arrange any type of transaction as a consequence of any information contained herein.

This document is issued by Elston Consulting Limited registered in England & Wales, registration number 07125478, registered office: 1 King William Street, London EC4N 7AF.

 $\ensuremath{\mathbb{C}}$ Elston Consulting Limited. All rights reserved $\:\:$ No unauthorised reproduction.